Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shanghai HeartCare Medical Technology's annualized ROCE % for the quarter that ended in Dec. 2025 was 6.47%.
Shanghai HeartCare Medical Technology (HKSE:06609) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Shanghai HeartCare Medical Technology ROCE % Related Terms
Shanghai HeartCare Medical Technology ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology ROCE % Chart
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology (HKSE:06609) has a ROCE % of 6.47% as of Dec. 2025.
Is Shanghai HeartCare Medical Technology's ROCE % too high?
Shanghai HeartCare Medical Technology's current ROCE % is 6.47%. The Medical Devices & Instruments industry median ROCE % is 3.25. Shanghai HeartCare Medical Technology's value of 6.47% is 99.1% above this industry median. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's ROCE % compare to ABT and SYK?
Shanghai HeartCare Medical Technology's ROCE % of 6.47% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 3.25. Shanghai HeartCare Medical Technology's value of 6.47% is 99.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 3.25, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai HeartCare Medical Technology's current ROCE % of 6.47% is 99.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai HeartCare Medical Technology's current ROCE % is 6.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current ROCE % is 6.47% and 99.1% above the Medical Devices & Instruments industry median of 3.25. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current ROCE % is 6.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued.
The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80.
GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.
Key valuation signals for HKSE:06609:
ROCE %: 6.47%
GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
Industry Position: 99.1% above the Medical Devices & Instruments median
No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score
Get the complete analysis for HKSE:06609
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06609 has been successfully added to your 
